GSK And Shionogi To Jointly Develop Super Bug Drug
This article was originally published in PharmAsia News
Shionogi and GlaxoSmithKline agreed to collaborate to research, develop and market novel cephem antibiotics targeting Gram-negative bacteria
You may also be interested in...
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.